Last reviewed · How we verify

NCT06298006: PASC24

A Two Year Longitudinal Clinical Study of Neurocognitive and Psychiatric Symptoms in Post COVID-19 Patients

Active, enrolled Last updated 11 February 2025
What this trial tests

trial testing Follow-up in COVID-19 in 57 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
22 February 2022
Primary endpoint
31 May 2026
30 June 2027

Quick facts

Lead sponsorRegion Örebro County
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment57
Start date22 February 2022
Primary completion31 May 2026
Estimated completion30 June 2027
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Region Örebro County — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prospective, longitudinal, open observational study monitors patients with cognitive and neuropsychological symptoms after COVID-19 infection, in a longitudinal manner to see how the disease has affected their physical, psychological and cognitive function, their ability to be active, return to work, their health-related quality of life in correlation with potential diagnostic and prognostic markers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Follow-up

Trials testing the same drug.

Other recruiting trials for COVID-19

Currently open trials in the same condition.

Other Region Örebro County trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06298006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing